2
Clinical Trials associated with Diphtheria, tetanus, pertussis and inactivated poliovirus vaccine(Boryung Pharmaceutical Co., Ltd.)A Multinational, Multicenter, Randomized, Comparative, Open-label, Phase 3 Study to Assess the Immunogenicity and Safety of DTaP-IPV (Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus) Vaccine Administered to Healthy Infants
The objective of this study is to assess the immunogenicity and safety of the DTaP-IPV combination vaccine compared with those of separate DTaP and IPV vaccines administered to healthy infants at 2, 4, and 6 months of age.
Immunogenicity and Safety of the DTaP-IPV (sanofi Pasteur Kitasato) Combined Vaccine (DD-687) given subcutaneously as a three-dose primary and booster vaccination versus commercially available DTaP (Kitasato) and Oral Polio Virus (OPV) Vaccines in Infants in Japan
Start Date20 Oct 2010 |
Sponsor / Collaborator- |
100 Clinical Results associated with Diphtheria, tetanus, pertussis and inactivated poliovirus vaccine(Boryung Pharmaceutical Co., Ltd.)
100 Translational Medicine associated with Diphtheria, tetanus, pertussis and inactivated poliovirus vaccine(Boryung Pharmaceutical Co., Ltd.)
100 Patents (Medical) associated with Diphtheria, tetanus, pertussis and inactivated poliovirus vaccine(Boryung Pharmaceutical Co., Ltd.)
100 Deals associated with Diphtheria, tetanus, pertussis and inactivated poliovirus vaccine(Boryung Pharmaceutical Co., Ltd.)